152 related articles for article (PubMed ID: 31704364)
1. From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years.
Rawson RV; Scolyer RA
Hum Pathol; 2020 Jan; 95():149-160. PubMed ID: 31704364
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
4. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
6.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens.
Lee PJ; Dennis K; Madan R; Fan F
Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186
[TBL] [Abstract][Full Text] [Related]
8. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
10. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
11. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
12. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
13. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
16. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
[No Abstract] [Full Text] [Related]
17. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
18. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
